MVA-CMDR

BIOLOGICAL3 trials

Sponsors

U.S. Army Medical Research and Development Command, Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV Infections

Phase 1

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

CompletedNCT00376090

U.S. Army Medical Research and Development CommandHIV Infections

Start: 2005-07-31End: 2008-12-31Updated: 2017-10-16

A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR

CompletedNCT01889719

Rockefeller UniversityHIV

Start: 2014-01-31End: 2015-05-31Updated: 2016-02-17

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

CompletedNCT02296541

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2014-12-31End: 2020-07-06Updated: 2023-04-24

Related Papers

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections2025-04-071 citations

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

Journal of Clinical Investigation2023-02-1412 citations

Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial

Journal of Clinical Investigation2021-11-306 citations

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review.

2013-01-1726 citations

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

2010-11-1567 citations